171178-47-5

Basic information

• Product Name: 6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE
• Synonyms: 6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE;6-Chloropyrido[3,4-d]pyrimidin-4(3H)-one;6-chloroPyrido[3,4-d]pyriMidin-4-one;6-chloropyrido[3,4-d]pyrimidin-4(1H)-one;6-Chloropyrido[3,4-d]pyrimidin-4(3H)
• CAS NO: 171178-47-5
• Molecular Formula: C₇H₄ClN₃O
• Molecular Weight: 181.58
• EINECS: 604-604-1
• Mol File: 171178-47-5.mol

Chemical Properties

• Boiling Point: 400.766ºC at 760 mmHg
• Flash Point: 196.176ºC
• Appearance: /
• Density: 1.668g/cm3
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.749
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.26±0.20(Predicted)
• CAS DataBase Reference: 6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE(171178-47-5)
• EPA Substance Registry System: 6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE(171178-47-5)

Safety Data

• Hazardous Substances Data: 171178-47-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE is used as a research compound for exploring its potential biological activities and interactions with biological targets. Its unique structure may allow it to modulate specific receptors or enzymes, which could be leveraged in the development of new therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE serves as a starting point for the design and synthesis of novel drug candidates. Its heterocyclic nature and chlorine substitution may contribute to the development of compounds with improved pharmacokinetic and pharmacodynamic properties.
Used in Drug Discovery:
6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE is utilized as a lead compound in drug discovery processes. Its potential biological activity and interactions with biological systems make it a valuable compound for further optimization and development into effective therapeutic agents.
Used in Chemical Synthesis:
6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE can be employed as a building block or intermediate in the synthesis of more complex molecules with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Biological Assays and Screening:
6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE is used in biological assays and high-throughput screening processes to evaluate its potential as a modulator of specific biological targets. The results from these assays can provide valuable insights into its mechanism of action and therapeutic potential.
Used in Toxicological Studies:
6-CHLORO-3H-PYRIDO[3,4-D]PYRIMIDIN-4-ONE may be utilized in toxicological studies to assess its safety profile and potential side effects, which is crucial for the development of safe and effective drugs.

InChI:InChI=1/C7H4ClN3O/c8-6-1-4-5(2-9-6)10-3-11-7(4)12/h1-3H,(H,10,11,12)

Upstream product

• 6313-33-3 formamidine hydrochloride 
• 58483-95-7 5‐amino‐2‐chloropyridine‐4‐carboxylic acid 
• 463-52-5 formamidine 
• 5350-93-6 6-Chloro-pyridin-3-ylamine 
• 171178-46-4 5-[N-(tert-butoxycarbonyl)amino]-2-chloropyridine-4-carboxylic acid 
• 171178-45-3 tert-butyl (6-chloropyridin-3-yl)carbamate 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 
• 3473-63-0 formamidine acetic acid 
• 77287-34-4 formamide 

Downstream Products

• 171178-48-6 4,6-dichloro-pyrido<3,4-d>pyrimidine 
• 189680-98-6 6-dimethylamino-3H-pyrido[3,4-d]pyrimidin-4-one 
• 602167-17-9 6-chloro-3-(3-fluoro-benzyl)-3H-pyrido[3,4-d]pyrimidin-4-one 
• 845639-56-7 4-(6-chloro-4-oxopyrido[3,4-d]pyrimidin-3-ylmethyl)benzoic acid tert-butyl ester 
• 1594729-07-3 6-(3-fluorophenyl)pyrido[3,4-d]pyrimidin-4-amine 
• 183741-98-2 6-methoxypyrido[3,4-d]pyrimidin-4(3H)-one 
• 202272-71-7 (2-benzyl-1H-benzimidazol-5-yl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine 
• 202272-68-2 GW2974 
• 202272-97-7 (1-Benzyl-1H-indol-5-yl)-(6-chloro-pyrido[3,4-d]pyrimidin-4-yl)-amine 
• 202272-67-1 (1-benzyl-1H-indazol-5-yl)-(6-chloropyrido[3,4-d]pyrimidin-4-yl)-amine 
• 189680-99-7 4-chloro-6-(N,N-dimethylamino)-pyrido[3,4-d]pyrimidine 

Relevant articles and documents

A convergent strategy towards febrifugine and related compounds

We report a modular five step synthetic route to the febrifugines that employs 2-(chloromethyl)allyl-trimethylsilane as a conjunctive reagent for the coupling of the piperidine and quinazolinone groups. We also demonstrate the application of a recent Rh-catalyzed quinazolinone synthesis for the facile generation of febrifugine analogs.

HETEROCYCLIC INHIBITORS OF TYROSINE KINASE

The present disclosure relates to heterocyclic compounds and methods which may be useful as inhibitors of HER2 or EGFR for the treatment or prevention of disease, including cancer.

Synthesis of Functionalized Pyridines via a Regioselective Oxazoline Promoted C-H Amidation Reaction

The first Rh-catalyzed C-H amidation of pyridines is reported. The incorporation of a substituent at the C2 position both is crucial to the success of this transformation and provides considerable scope for further elaboration of the resulting products. Among these compounds, 2-chloropyridines allow access to a selection of intermediates including a versatile azaquinazoline scaffold.

A pyrido [3,4-d] pyrimidine -4 (3H)-one derivatives method for the preparation of

Belonging to the field of chemical synthesis, the invention discloses a preparation method for a pyridine[3, 4-d]pyrimidine-4(3H)-one derivative. The method includes: taking a 3-aminopyridine-4-carboxylic acid compound and an amidine compound as raw materials, adopting sodium acetate as a nucleophilic catalyst, subjecting the reaction system to reflux reaction for 4-10h in an organic solvent, and carrying out TLC detection, washing, extraction, concentration, beating and filtering so as to obtain the product pyridine[3, 4-d]pyrimidine-4(3H)-one derivative. The 3-aminopyridine-4-carboxylic acid compound, the amidine compound and sodium acetate are in a mole ratio of 1:3-5:2-4. The method provided by the invention has the advantages of easily available raw materials, mild reaction condition, well operable after-treatment, higher yield, and easy realization of large scale production.

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.

Discovery of selective 4-amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization

Mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) is a serine/threonine kinase implicated in the regulation of many biological processes. A fragment-based lead discovery approach was used to generate potent and selective MAP4K4 inhibitors. The fragment hit pursued in this article had excellent ligand efficiency (LE), an important attribute for subsequent successful optimization into drug-like lead compounds. The optimization efforts eventually led us to focus on the pyridopyrimidine series, from which 6-(2-fluoropyridin-4-yl)pyrido[3,2-d]pyrimidin-4-amine (29) was identified. This compound had low nanomolar potency, excellent kinase selectivity, and good in vivo exposure, and demonstrated in vivo pharmacodynamic effects in a human tumor xenograft model.

PYRIMIDO [5,4-D] PYRIMIDINE DERIVATIVES FOR THE INHIBITION OF TYROSINE KINASES

The present invention encompasses compounds of general formula (1), wherein the groups R1 to R4, X1, X2, X3, X4, X5, Q, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, as well as pharmaceutical preparations and formulations of these compounds.

PYRIDO [3,4-D] PYRIMIDINE DERIVATIVES AS MATRIX METALLOPROTEINASE-13 INHIBITORS

This invention relates to a pyrido[3,4-d]pyrimidine derivative of Formula (I), or a pharmaceutically acceptable salt thereof, wherein R, L', L2, V, L3, and R2 are as defined in the specification, that inhibits a matrix metalloproteinase-13 enzyme and thus is useful for treating diseases resulting from MMP-13 mediated tissue breakdown such as osteoarthritis, rheumatoid arthritis, cartilage damage, psoriatic arthritis, ankylosing spondylitis, heart failure, atherosclerosis, inflammatory bowel disease, multiple sclerosis, age-related macular degeneration, chronic obstructive pulmonary disease, asthma, periodontal diseases, psoriasis, cancer, and osteoporosis.

Anilinoquinazaolines as protein tyrosine kianse inhibitors

Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.

Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and c-erbB-2

Described herein is the design and synthesis of indazolylaminopyridopyrimidines and quinazolines as inhibitors of the class 1 tyrosine kinase receptor family. Data is presented for N4-(1-benzyl-1H-indazol-5-yl)-N6,N6- dime